Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer...
Eli Lilly & Co. (LLY) has a valuation score of 67/100 (moderate), profitability score of 100/100 (strong), financial health score of 67/100 (moderate), Piotroski F-Score of 7/9, Altman Z-Score of 8.36 (safe zone), revenue growth of +31.7% YoY.
Neutral
Analyst Consensus
Strong BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026
Analyst Recommendations38 analysts · 2026-08-01
11
19
7
Strong Buy 11Buy 19Hold 7Sell 1Strong Sell 0
Recent Market Moves
See all LLY moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Aug 26 | Regular | $1192.39 | -3.35% | -2.23 |
| Aug 5 | Pre-market | $1165.11 | +4.43% | 2.95 |
| Aug 5 | Regular | $1166.85 | +4.59% | 3.06 |
| Aug 5 | After-hours | $1175.94 | +5.40% | 3.60 |